Get the Stockscreener App
24.27
2.37%
-0.5929
Catalyst Pharmaceuticals Inc stock is traded at $24.27, with a volume of 618.69K.
It is down -2.37% in the last 24 hours and up +1.17% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$24.86
Open:
$24.485
24h Volume:
618.69K
Relative Volume:
0.53
Market Cap:
$2.98B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
20.57
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
-0.61%
1M Performance:
+1.17%
6M Performance:
+21.72%
1Y Performance:
+17.93%
1-Day Range:
$23.50
$24.70
1-Week Range:
$23.50
$25.00
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.27 | 3.06B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.16 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.17 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
775.20 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.56 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
321.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus
Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks
Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria
Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada
Catalyst: Q4 Financial Results Overview - Bitget
Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn
CEO Change: Is Catalyst Pharmaceuticals Inc a top pick in the sectorQuarterly Market Review & Safe Capital Preservation Plans - baoquankhu1.vn
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX) - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Finviz
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for - Finviz
Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday - MarketBeat
Catalyst Pharmaceuticals (CPRX) Stock Analysis: 42% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Aug Retail: Is Catalyst Pharmaceuticals Inc a momentum stock2025 Retail Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc.’s growth already priced inTrade Exit Summary & Fast Gain Stock Trading Tips - mfd.ru
Is Catalyst Pharmaceuticals Inc. stock attractive for hedge fundsJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - mfd.ru
What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Will Catalyst Pharmaceuticals Inc. benefit from government policy2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Block Trades: Is iShares Gold Trust impacted by rising ratesInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - GlobeNewswire
Catalyst Pharmaceuticals (CPRX) Investor Outlook: A Promising 41.4% Upside Potential - DirectorsTalk Interviews
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Renewed Interest And Pocket Pivot Signal - Sahm
Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup - ChartMill
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years - Yahoo Finance
What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - Mfd.ru
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Federated Hermes Inc. - MarketBeat
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Growth Strength And Positive Analyst Sentiment - Sahm
Aug Reactions: Is EDHL subject to activist investor interest2025 Volume Leaders & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)? - Sahm
Ruffer LLP Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock - Chartmill
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Exploring A 45% Upside Potential - DirectorsTalk Interviews
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Y Intercept Hong Kong Ltd - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - The Motley Fool
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Fresh Rare Disease Momentum And Earnings Outperformance - Sahm
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory - Insider Monkey
Campbell & CO Investment Adviser LLC Has $1.93 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
How Investors May Respond To Catalyst Pharmaceuticals (CPRX) Rare-Disease Strength And Potential Technical Breakout - Sahm
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
0.66%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):